US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Binah Capital Group Inc

2.00

-0.0900-4.31%

Post-market: 1.97-0.0300-1.50%17:56 EDT

Volume:21.62K

Turnover:43.71K

Market Cap:33.20M

PE:-17.05

High:2.10

Open:2.10

Low:1.95

Close:2.09

Loading ...

Overview Company News Filings

Binah Capital Group Inc. Conducted Annual Stockholders Meeting

Will a $10,000 Investment in Solana Turn Into $1 Million by 2035?

Could XRP Reach $10 if It Conquers This 1 Massive Future Market?

Press Release: enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

J.P. Morgan Initiates a Buy Rating on Baltic Classifieds Group Plc (BCG)

BCG Fires Two Partners Over Gaza Aid Work -- WSJ

Promising Potential of Protara Therapeutics’ TARA-002 in Addressing BCG Shortages for NMIBC Treatment

What is the Gaza Humanitarian Foundation, the aid group backed by the US and Israel?

Press Release: Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

CORRECTION: Binah Capital Group Q1 EPS $0.06 Up From $(0.14) YoY, Sales $48.94M Up From $41.45M YoY

Press Release: Binah Capital Group Reports First Quarter 2025 Results

Binah Capital Group Reports Q1 2025: Revenue Up 18% to $49M, Net Income at $1M

Press Release: JLL announces senior leadership appointments

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion

Press Release: Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer

Buy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG Shortage

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","market":"US","secType":"STK","nameCN":"Binah Capital Group Inc","latestPrice":2,"timestamp":1754078400000,"preClose":2.09,"halted":0,"volume":21615,"hourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":2,"latestTime":"17:56 EDT","volume":97,"amount":193.4500003,"timestamp":1754085406127},"delay":0,"floatShares":3036659,"shares":16602460,"eps":-0.117335,"marketStatus":"Post-Mkt","change":-0.09,"latestTime":"08-01 19:59:24 EDT","open":2.1,"high":2.1,"low":1.95,"amount":43706.481060000006,"amplitude":0.07177,"askPrice":2.06,"askSize":100,"bidPrice":1.97,"bidSize":62,"shortable":3,"etf":0,"ttmEps":-0.117335,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1754092800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.09,"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":2,"latestTime":"17:56 EDT","volume":97,"amount":193.4500003,"timestamp":1754085406127},"volumeRatio":1.201234},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","floatShares":3036659,"roa":"-2.91%","roe":"-11.19%","lyrEps":-0.318929,"volumeRatio":1.201234,"shares":16602460,"dividePrice":0,"high":2.1,"amplitude":0.07177,"preClose":2.09,"low":1.95,"week52Low":1.71,"pbRate":"86.02","psRate":"0.19","week52High":6.55,"institutionHeld":0,"latestPrice":2,"committee":-0.234568,"eps":-0.117335,"divideRate":0,"volume":21615,"delay":0,"ttmEps":-0.117335,"open":2.1,"prevYearClose":2.94,"prevWeekClose":2.35,"prevMonthClose":2.09,"prevQuarterClose":2.04,"fiveDayClose":2.35,"twentyDayClose":2,"sixtyDayClose":2.236},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546721442","title":"Binah Capital Group Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546721442","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546721442?lang=en_us&edition=fundamental","pubTime":"2025-06-28 04:49","pubTimestamp":1751057362,"startTime":"0","endTime":"0","summary":"Binah Capital Group Inc. held its annual stockholder meeting on June 27, 2025. During the meeting, stockholders voted on two key proposals. The first proposal involved the election of David Crane and Joel Marks as Class I Directors, which was approved. The second proposal was the ratification of FGMK, LLP as the independent registered public accounting firm for the year ending December 31, 2025, and this was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Binah Capital Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 27, 2025, and is solely responsible for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL8DzmfL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2546690715","title":"Will a $10,000 Investment in Solana Turn Into $1 Million by 2035?","url":"https://stock-news.laohu8.com/highlight/detail?id=2546690715","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546690715?lang=en_us&edition=fundamental","pubTime":"2025-06-27 17:00","pubTimestamp":1751014800,"startTime":"0","endTime":"0","summary":"Solana is gaining traction with asset managers and crypto app developers.Its price has a habit of going up sharply over time.But a lot needs to go right for it to deliver a truly gargantuan return in 10 years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/27/will-a-10000-investment-in-solana-turn-into-1-mill/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2543690746","title":"Could XRP Reach $10 if It Conquers This 1 Massive Future Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2543690746","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543690746?lang=en_us&edition=fundamental","pubTime":"2025-06-15 20:05","pubTimestamp":1749989100,"startTime":"0","endTime":"0","summary":"Real-world assets are increasingly being tracked on blockchains.XRP has a lot of features that asset managers need to do that gracefully.Competitors could still make hitting $10 pretty difficult in the near term.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/15/could-xrp-reach-10-if-it-conquers-this-1-massive-f/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2542151963","title":"Press Release: enGene Reports Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151963","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151963?lang=en_us&edition=fundamental","pubTime":"2025-06-12 20:00","pubTimestamp":1749729600,"startTime":"0","endTime":"0","summary":"Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025. Biologics License Application  filing planned for mid-2026 remains on track. EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application. Cash and marketable securities of $251.5 million expected to provide runway into 2027. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update.\"We have seen strong enrollment in the pivotal cohort of our LEGEND study,\" said Ron Cooper, Chief Executive Officer of enGene. \"This positions us to stay on track for our planned trial updates across all cohorts in the second half of 2025 and a potential BLA filing in mid-2026, advancing our goal to introduce a novel, non-viral therapy that could redefine treatment for pati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4589","CMA","BK4022","ENGN","R","BK4588","BK4139","BK4207","BK4585","BCG","EMA","BK4211","BK4232","BK4135","BK4081"],"gpt_icon":0},{"id":"2541835976","title":"J.P. Morgan Initiates a Buy Rating on Baltic Classifieds Group Plc (BCG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2541835976","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541835976?lang=en_us&edition=fundamental","pubTime":"2025-06-06 15:15","pubTimestamp":1749194115,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Marcus Diebel from J.P. Morgan initiated coverage with a Buy rating on Baltic Classifieds Group Plc (BCG – Research...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-initiates-a-buy-rating-on-baltic-classifieds-group-plc-bcg-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-initiates-a-buy-rating-on-baltic-classifieds-group-plc-bcg-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCG"],"gpt_icon":0},{"id":"2541000583","title":"BCG Fires Two Partners Over Gaza Aid Work -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2541000583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541000583?lang=en_us&edition=fundamental","pubTime":"2025-06-06 09:10","pubTimestamp":1749172200,"startTime":"0","endTime":"0","summary":"Boston Consulting Group said it fired two North American partners involved in an Israeli-American effort to distribute humanitarian aid in Gaza.The consulting giant terminated the two unnamed partners after an internal investigation found they didn't disclose details about the pro-bono project during a client vetting process.\"In violation of BCG's policies and protocols, the partners carried out subsequent unauthorized work,\" the firm said in a written statement.\"The two partners failed to disclose the full nature of the work during the client acceptance process,\" the firm said in a written statement. \"We deeply regret that in this situation we did not live up to our standards.\". The controversy over BCG's involvement in Gaza is only the latest example of U.S. consulting firms facing challenges in the Middle East. Executives at BCG, McKinsey and other consulting firms appeared before a Senate subcommittee last year to discuss their work in Saudi Arabia. But, despite the complexities, c","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2541077153","title":"Promising Potential of Protara Therapeutics’ TARA-002 in Addressing BCG Shortages for NMIBC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2541077153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541077153?lang=en_us&edition=fundamental","pubTime":"2025-06-06 00:55","pubTimestamp":1749142519,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Protara Therapeutics (TARA – Research Report). The associated price target i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-protara-therapeutics-tara-002-in-addressing-bcg-shortages-for-nmibc-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-protara-therapeutics-tara-002-in-addressing-bcg-shortages-for-nmibc-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARA","BCG","BK4139","BK4135"],"gpt_icon":0},{"id":"2540055104","title":"What is the Gaza Humanitarian Foundation, the aid group backed by the US and Israel?","url":"https://stock-news.laohu8.com/highlight/detail?id=2540055104","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540055104?lang=en_us&edition=fundamental","pubTime":"2025-06-04 14:28","pubTimestamp":1749018519,"startTime":"0","endTime":"0","summary":"Over the past two weeks, a new Gaza aid group has been at work in the Palestinian territory, bypassing the longstanding UN-led aid system there with a new distribution mechanism and drawing criticism over various issues.The Gaza Humanitarian Foundation , backed by the United States and Israel, said on Tuesday  that it has given out more than seven million meals from its aid centres \"without incident\".However, the Israeli military is facing allegations of shooting into crowds of civilians rushing to pick up aid packages near GHF sites, which it denies. On Tuesday, emergency responders said Israel's military killed at least 27 people near a GHF centre in Gaza, a figure later corroborated by the Red Cross.The United Nations has also denounced the foundation and refused to cooperate with it over concerns it was designed to cater to Israeli military objectives.Here's what you need to know about the GHF and recent developments involving its aid operations in Gaza.Moore, an adviser to US Pres","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--1-hjxPeN--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/04/000_48hy8g3.jpg?itok=fdF5UMNS","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--1-hjxPeN--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/04/000_48hy8g3.jpg?itok=fdF5UMNS"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/world/gaza-humanitarian-foundation-ghf-israel-us-aid-5165181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2540371806","title":"Press Release: Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540371806","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540371806?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:04","pubTimestamp":1748894640,"startTime":"0","endTime":"0","summary":"NEW YORK, June 02, 2025  -- Protara Therapeutics, Inc. , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William \"Bill\" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara.Mr. Conkling most recently served as President and Chief Executive Officer of Rafael Holdings, Inc., a holding company with interests in clinical and early-stage pharmaceutical companies. Prior to assuming his role as Chief Executive Officer, he served as the company's Chief Commercial and Business Officer where he was responsible for building the commercial organization and developing the go-to-market strategy for the company's assets.Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BCG","LENZ","BK4139","TARA","BK4135","BK4007"],"gpt_icon":0},{"id":"2535806621","title":"CORRECTION: Binah Capital Group Q1 EPS $0.06 Up From $(0.14) YoY, Sales $48.94M Up From $41.45M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535806621","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535806621?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:38","pubTimestamp":1747345119,"startTime":"0","endTime":"0","summary":"Binah Capital Group (NASDAQ:BCG) reported quarterly earnings of $0.06 per share. This is a 142.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported $48.94 million in sales this quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45456389/correction-binah-capital-group-q1-eps-0-06-up-from-0-14-yoy-sales-48-94m-up-from-41-45m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG"],"gpt_icon":0},{"id":"2535570806","title":"Press Release: Binah Capital Group Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535570806","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535570806?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:36","pubTimestamp":1747344960,"startTime":"0","endTime":"0","summary":"- Grew Total Revenue 18% Year-over-Year to $49 Million -. - Assets Under Management  Increased 3% Year-over-Year to $26 Billion -. \"We once again delivered strong results, which is a continued testament to our differentiated RIA platform,\" stated Craig Gould, Chief Executive Officer of Binah Capital Group. \"Highlighting our business model's sustained momentum and the effective execution of our growth initiatives, we achieved double-digit year-over-year growth in both revenue and EBITDA while delivering GAAP profitability in the first quarter. Subsequent to quarter-end, we were pleased to welcome Bleakley Financial Group to the Binah family, underscoring the strength of our open-architecture platform and the confidence that leading entrepreneurial firms place in Binah. Additionally, we further expanded and strengthened our executive leadership with the appointment of Ryan Marcus as our Chief Business Development and Engagement Officer. Looking ahead, we believe our resilient and differe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2535050468","title":"Binah Capital Group Reports Q1 2025: Revenue Up 18% to $49M, Net Income at $1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2535050468","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535050468?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:25","pubTimestamp":1747344355,"startTime":"0","endTime":"0","summary":"Binah Capital Group Inc. reported its first-quarter 2025 results, highlighting an 18% year-over-year increase in total revenue, reaching $49 million. The company achieved a net income of $1 million, a significant improvement from the GAAP net loss of $1.6 million recorded in the same period last year. EBITDA also saw a notable rise, increasing to $2.2 million from $0.0 million in the prior-year period, driven by higher revenue growth and a reduction in expenses. The company reported a 3% year-over-year growth in assets under management, totaling $26 billion. Gross profit for the first quarter amounted to $8.6 million, up from $7.8 million in the previous year, while total operating expenses decreased to $7 million from $10 million, largely due to the absence of prior-year costs related to a business combination. A significant operational update included the acquisition of Bleakley Financial Group, enhancing Binah's open-architecture platform. The company also strengthened its leadershi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDLKp4Jh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG"],"gpt_icon":0},{"id":"2533998945","title":"Press Release: JLL announces senior leadership appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2533998945","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533998945?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:36","pubTimestamp":1746617760,"startTime":"0","endTime":"0","summary":"Karen Brennan appointed Chief Executive Officer of Leasing Advisory business globally. Kelly Howe to serve as next Chief Financial Officer of JLL. CHICAGO, May 7, 2025 /PRNewswire/ -- JLL today announced the following senior leadership appointments, effective July 1, 2025.Karen Brennan, who has served for the past five years as the company's Chief Financial Officer and sits on JLL's Global Executive Board, has been appointed as Chief Executive Officer of JLL's Leasing Advisory business globally.Christian Ulbrich, President and CEO of JLL, said, \"Throughout Karen's more than 25 year tenure at JLL she has taken on numerous leadership roles across the business globally, and exemplified strategic vision, excellence in execution and dedication to our clients. This appointment recognizes the contributions Karen has made to JLL's success, and our confidence in her ability to drive continued value for the stakeholders we serve.\". During the course of her more than 25 years of experience, Karen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054578231.USD","JLL","BK4135","BK6039","BK6520","NEX.SI","BK4079","BCG"],"gpt_icon":0},{"id":"2533585058","title":"Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533585058","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533585058?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:49","pubTimestamp":1746445740,"startTime":"0","endTime":"0","summary":"The U.S. FDA has approved SELARSDI  as interchangeable with the reference biologic Stelara  in all presentations matching the reference product, effective as of April 30, 2025. SELARSDI is approved for all indications matching the reference product. SELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn’s disease and ulcerative colitis. PARSIPPANY, N.J. & REYKJAVK, Iceland, May 05, 2025  -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech  today announced that the U.S. Food and Drug Administration  has approved SELARSDI  injection as interchangeable with the reference biologic Stelara . As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic art","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-alvotech-announce-fda-approval-114900298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALVOW","BK4139","BCG","BK4516","BK4574","BK4585","BK4171","FR","F","BK4099","BK4156","BK4224","BK4588","BK4555","ALVO","TEVA","BK4135"],"gpt_icon":0},{"id":"2532076959","title":"Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2532076959","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532076959?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:38","pubTimestamp":1746099515,"startTime":"0","endTime":"0","summary":"Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion. Binah Capital Group Inc. announced the appointment of Ryan Marcus as Chief Business Development and Engagement Officer. Marcus will collaborate with Binah Capital's broker-dealers to develop and implement long-term business strategies, aiming to enhance market presence and drive sustainable growth. His experience in strategic growth execution and wealth management is expected to contribute significantly to the company's objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Binah Capital Group Inc. published the original content used to generate this news brief via GlobeNewswire ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL5gbpCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LU2210149790.SGD","BCG","BK4585","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4588","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2532075023","title":"Press Release: Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075023?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:38","pubTimestamp":1746099480,"startTime":"0","endTime":"0","summary":"Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer. In his new role, Mr. Marcus will work closely with Binah Capital's broker-dealers, including PKS Investments, Cabot Lodge Securities and World Equity Group, to develop and implement long-term business strategies. He will focus on enhancing market presence, building a unified value proposition and driving sustainable growth across the organization.\"Ryan is a rare talent and industry builder who understands how trust, transparency and long-term value are created and maintained,\" said Craig Gould, CEO of Binah Capital Group. \"His deep relationships and intuitive grasp of the advisor landscape will strengthen our ability to deliver unparalleled support to our partners. We're thrilled to welcome him as a senior executive at Binah and look forward to working together to execute on our strategic growth plans.\". Binah Capital Group (\"Binah Capital\", ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4108","BK4120","MCS","TISI","BK4135"],"gpt_icon":0},{"id":"2531733861","title":"Buy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733861","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733861?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:15","pubTimestamp":1745928946,"startTime":"0","endTime":"0","summary":"Analyst Alec Stranahan of Bank of America Securities maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-cretostimogenes-potential-in-bladder-cancer-treatment-amid-bcg-shortage?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-cretostimogenes-potential-in-bladder-cancer-treatment-amid-bcg-shortage?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCG","CGON","CG"],"gpt_icon":0},{"id":"2531869477","title":"Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware","url":"https://stock-news.laohu8.com/highlight/detail?id=2531869477","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531869477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025----Merck , known as MSD outside of the United States and Canada, announced today the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware.A cornerstone of Merck’s continued commitment to investing in American innovation and infrastructure, Merck Wilmington Biotech will comprise laboratory, manufacturing and warehouse capabilities to enable the launch and commercial production of next-generation biologics and therapies including potent antibody-drug conjugates , reinforcing Merck’s focus on expanding and diversifying its pipeline.With proximity to Delaware and Pennsylvania universities, Merck Wilmington Biotech will also attract talented students and professionals, supporting community growth and development. The site’s proximity to Merck’s existing facilities ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-breaks-ground-1-billion-104500898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0965508806.USD","MRK","DM","LU2324357040.USD","CRC","LU0965509010.AUD","CPS","BK4588","IE00BJT1NW94.SGD","LU0208291251.USD","LU1974910355.USD","LU0122379950.USD","LU1035773651.USD","LU0265550946.USD","LU2361045086.USD","BK4533","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1116320901.HKD","SG9999001440.SGD","HCC","LU1929549753.HKD","LU1585245621.USD","LU1066053197.SGD","LU1069347547.HKD","BK4161","LU2023250504.SGD","LU1066051811.HKD","LU1983299246.USD","BCG","CRT","LU0320765646.SGD","LU0965509283.SGD","SG9999002224.SGD","LU0861579265.USD","BK4559","RCC","SG9999015341.SGD","BK4585","LU1116320737.USD","BK4516","BTC","ALT","LU2468319806.SGD","LU1066051498.USD","HSCT","LU1023059063.AUD","BK4135","LU1291159041.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2531816437","title":"Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531816437","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531816437?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment. NEW YORK, April 29, 2025----Pfizer Inc.  reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance.\"Our overall solid first-quarter performance demonstrates our continued focus on commercial execution amid U.S. Medicare Part D headwinds. Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range.\". First-Quarter 2025 Revenues of $13.7 Billion, Reported Diluted EPS of $0.52, and Adjusted Diluted EPS of $0.92. On Track to Deliver Operating Margin Expansion from Ongoing Cost Realignment Program with Approximately $4.5 Billion of Net Cost Savings by End of 2025, and Announces Additional Productivity Gains Expected Through 2027 Leveraging Digital Enablement and Process Simplification. First Phase of Manufacturing Optimizatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-solid-first-quarter-104500122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234572021.USD","BK4585","ITT","BK4534","LU0054578231.USD","CDC","BK4195","BK4135","LU0225284248.USD","BK4533","PFE","LU1066051498.USD","LU1894683264.USD","BK4535","LU0053671581.USD","SOC","BK4548","IE0002270589.USD","BK4213","LU0170899867.USD","LU1066053197.SGD","BK4550","CAR","LU0225771236.USD","LU0058720904.USD","BCG","IE00B19Z3581.USD","SG9999002232.USD","LU0289739699.SGD","IE000M9KFDE8.USD","BK4230","LU0321505439.SGD","BK4599","BNTX","EC","LU1894683348.USD","SG9999013999.USD","LU0321505868.SGD","OS","BK4568","LU0868494617.USD","LU0122379950.USD","PFS","SG9999002224.SGD","LU1057294990.SGD","BK4022","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4581"],"gpt_icon":1},{"id":"2531912232","title":"CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2531912232","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531912232?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:14","pubTimestamp":1745853277,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc.  announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at the 2025 American Urological Association Annual Meeting.The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer  unresponsive to Bacillus Calmette Guerin  treatment with carcinoma in situ  with or without Ta or T1 disease.The study reported 75.5% complete response  at any time, with 34 confirmed CRs at 24 months and nine patients pending their 24-month assessment as of the March 14, 2025, cutoff date.Also Read: ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug. The 12—and 24-month CR rates are 50.7% and 42.3%, respectively, by K-M estimation.The median duration of response  is 28 months and ongoing. Notably, 97.3% of patients were free from progression to muscle-invasive disease at 24 months.Additionally, Cohort P, in patients with BCG-unresponsive Ta/T1 disease without CIS, showed an estimated 90.5% high-grade r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncologys-bladder-cancer-drug-151437058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","CGON","BK4139","CG","ISBC","BK4135","BK4211","CR","IE00B3QW5Z07.USD","BK4161","BCG","IE00B64PRP62.GBP"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":84,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCG","date":"2025-07-31","current":-19.005896,"percent":0.202572,"low":-94.684933,"twenty":-19.142262,"median":-11.416343,"eighty":-7.649141,"high":216.897522,"avg":-0.478968,"sd":54.116437,"marketCap":37023485},"quantilePoints":[{"date":"2024-04-12","current":47.846282,"twenty":47.314657,"median":50.799756,"eighty":52.276493,"marketCap":133339024},{"date":"2024-04-19","current":40.132439,"twenty":41.297957,"median":46.73873,"eighty":50.917895,"marketCap":111841925},{"date":"2024-04-26","current":203.935518,"twenty":44.420253,"median":50.799756,"eighty":187.977853,"marketCap":116447181},{"date":"2024-05-03","current":181.468046,"twenty":45.542573,"median":118.644354,"eighty":199.211588,"marketCap":103618254},{"date":"2024-05-10","current":158.424485,"twenty":47.403261,"median":158.424485,"eighty":194.026786,"marketCap":90460381},{"date":"2024-05-17","current":135.380923,"twenty":48.08256,"median":150.76106,"eighty":191.347973,"marketCap":77302507},{"date":"2024-05-24","current":216.897522,"twenty":50.268131,"median":142.815352,"eighty":191.347973,"marketCap":123848485},{"date":"2024-05-31","current":-70.098677,"twenty":46.96024,"median":139.70159,"eighty":188.726768,"marketCap":145945446},{"date":"2024-06-07","current":-77.180156,"twenty":40.710114,"median":130.655552,"eighty":184.646906,"marketCap":160689084},{"date":"2024-06-14","current":-52.991736,"twenty":-57.718026,"median":121.266741,"eighty":182.34255,"marketCap":110328794},{"date":"2024-06-21","current":-39.863152,"twenty":-52.943996,"median":66.796341,"eighty":180.865278,"marketCap":82995083},{"date":"2024-06-28","current":-46.865063,"twenty":-56.142596,"median":53.605557,"eighty":179.659743,"marketCap":97573062},{"date":"2024-07-05","current":-45.194153,"twenty":-52.896255,"median":49.470693,"eighty":176.203209,"marketCap":94094226},{"date":"2024-07-12","current":-42.966272,"twenty":-51.448132,"median":45.631177,"eighty":169.370177,"marketCap":89455779},{"date":"2024-07-15","current":-46.626362,"twenty":-50.795682,"median":45.409667,"eighty":167.641909,"marketCap":97076086},{"date":"2024-08-02","current":-31.986002,"twenty":-50.143231,"median":45.188156,"eighty":165.913642,"marketCap":66594857},{"date":"2024-08-09","current":-28.166778,"twenty":-49.363473,"median":40.613835,"eighty":159.576663,"marketCap":58643232},{"date":"2024-08-16","current":-20.272151,"twenty":-47.35838,"median":-24.029285,"eighty":158.424485,"marketCap":59802844},{"date":"2024-08-23","current":-19.247598,"twenty":-46.674102,"median":-19.602159,"eighty":156.120128,"marketCap":56780413},{"date":"2024-08-30","current":-19.866672,"twenty":-46.24444,"median":-19.585275,"eighty":147.891273,"marketCap":58606683},{"date":"2024-09-06","current":-18.302664,"twenty":-45.957998,"median":-19.585275,"eighty":144.080444,"marketCap":53992860},{"date":"2024-09-13","current":-15.251751,"twenty":-45.448768,"median":-19.106899,"eighty":140.947095,"marketCap":44992666},{"date":"2024-09-20","current":-16.883858,"twenty":-45.194153,"median":-18.403405,"eighty":138.834001,"marketCap":49807380},{"date":"2024-09-27","current":-18.009448,"twenty":-45.194153,"median":-18.156337,"eighty":136.530797,"marketCap":53127872},{"date":"2024-10-04","current":-14.801515,"twenty":-45.098673,"median":-18.009448,"eighty":129.710478,"marketCap":43664469},{"date":"2024-10-11","current":-15.139192,"twenty":-44.271652,"median":-17.794742,"eighty":123.304944,"marketCap":44660617},{"date":"2024-10-18","current":-13.732204,"twenty":-43.642912,"median":-16.883858,"eighty":121.209133,"marketCap":40510002},{"date":"2024-10-25","current":-11.706141,"twenty":-43.204974,"median":-16.377341,"eighty":95.05469,"marketCap":34533116},{"date":"2024-10-31","current":-12.147373,"twenty":-41.725024,"median":-16.067805,"eighty":68.991477,"marketCap":35834749},{"date":"2024-11-08","current":-12.325216,"twenty":-38.781038,"median":-15.870826,"eighty":54.048578,"marketCap":36359387},{"date":"2024-11-15","current":-19.641554,"twenty":-35.089122,"median":-15.983385,"eighty":51.154173,"marketCap":57942585},{"date":"2024-11-22","current":-9.482521,"twenty":-31.222157,"median":-15.814546,"eighty":49.736506,"marketCap":41174100},{"date":"2024-11-29","current":-9.867391,"twenty":-29.805862,"median":-15.758267,"eighty":48.08256,"marketCap":42834346},{"date":"2024-12-06","current":-9.217214,"twenty":-28.707835,"median":-15.561288,"eighty":47.403261,"marketCap":40011928},{"date":"2024-12-13","current":-11.205991,"twenty":-28.548701,"median":-15.251751,"eighty":45.542573,"marketCap":48645207},{"date":"2024-12-20","current":-8.873003,"twenty":-28.103124,"median":-15.039858,"eighty":44.420253,"marketCap":38517707},{"date":"2024-12-27","current":-11.66494,"twenty":-27.84851,"median":-14.773376,"eighty":41.348639,"marketCap":50637503},{"date":"2025-01-03","current":-10.555814,"twenty":-27.84851,"median":-14.407558,"eighty":41.145913,"marketCap":45822789},{"date":"2025-01-10","current":-10.364586,"twenty":-27.132405,"median":-13.712083,"eighty":40.517556,"marketCap":44992666},{"date":"2025-01-17","current":-9.599672,"twenty":-25.795677,"median":-13.338247,"eighty":11.509386,"marketCap":41672174},{"date":"2025-01-24","current":-9.561426,"twenty":-24.74539,"median":-12.325216,"eighty":-7.572649,"marketCap":41506150},{"date":"2025-01-31","current":-8.069843,"twenty":-22.526431,"median":-12.059139,"eighty":-7.572649,"marketCap":35031190},{"date":"2025-02-07","current":-8.299318,"twenty":-20.109959,"median":-11.84684,"eighty":-7.649141,"marketCap":36027338},{"date":"2025-02-14","current":-7.955106,"twenty":-19.799137,"median":-11.755302,"eighty":-7.809773,"marketCap":34533116},{"date":"2025-02-21","current":-7.534404,"twenty":-19.697834,"median":-11.685541,"eighty":-7.672088,"marketCap":32706846},{"date":"2025-02-28","current":-10.976517,"twenty":-19.697834,"median":-11.593582,"eighty":-7.542053,"marketCap":47649060},{"date":"2025-03-07","current":-8.567038,"twenty":-19.686578,"median":-11.300169,"eighty":-7.572649,"marketCap":37189510},{"date":"2025-03-14","current":-7.381421,"twenty":-19.641554,"median":-11.255905,"eighty":-7.572649,"marketCap":32042747},{"date":"2025-03-21","current":-7.151947,"twenty":-19.630298,"median":-11.225114,"eighty":-7.350824,"marketCap":31046600},{"date":"2025-03-28","current":-7.687386,"twenty":-19.585275,"median":-11.1295,"eighty":-7.412018,"marketCap":33370944},{"date":"2025-04-04","current":-7.242195,"twenty":-19.569517,"median":-10.842657,"eighty":-7.32062,"marketCap":33038895},{"date":"2025-04-11","current":-6.987445,"twenty":-19.454706,"median":-10.555814,"eighty":-7.159596,"marketCap":31876723},{"date":"2025-04-17","current":-7.496946,"twenty":-19.247598,"median":-10.43842,"eighty":-7.190192,"marketCap":34201067},{"date":"2025-04-25","current":-8.006447,"twenty":-18.9662,"median":-10.135111,"eighty":-7.242195,"marketCap":36525412},{"date":"2025-05-02","current":-8.388573,"twenty":-18.90992,"median":-9.982129,"eighty":-7.266684,"marketCap":38268670},{"date":"2025-05-09","current":-7.860875,"twenty":-18.572243,"median":-9.867391,"eighty":-7.314981,"marketCap":35861313},{"date":"2025-05-16","current":-8.406769,"twenty":-18.572243,"median":-9.867391,"eighty":-7.343175,"marketCap":38351682},{"date":"2025-05-23","current":-20.369548,"twenty":-19.247598,"median":-9.867391,"eighty":-7.381421,"marketCap":39679879},{"date":"2025-05-30","current":-18.835439,"twenty":-19.522241,"median":-9.943883,"eighty":-7.381421,"marketCap":36691436},{"date":"2025-06-06","current":-18.153613,"twenty":-19.522241,"median":-10.135111,"eighty":-7.442614,"marketCap":35363239},{"date":"2025-06-13","current":-17.471788,"twenty":-19.299375,"median":-10.401503,"eighty":-7.489139,"marketCap":34035043},{"date":"2025-06-20","current":-17.216103,"twenty":-19.209964,"median":-10.536691,"eighty":-7.518782,"marketCap":33536969},{"date":"2025-06-27","current":-17.045647,"twenty":-19.179762,"median":-10.708797,"eighty":-7.533978,"marketCap":33204920},{"date":"2025-07-03","current":-17.045647,"twenty":-19.092292,"median":-11.091254,"eighty":-7.534404,"marketCap":33204920},{"date":"2025-07-11","current":-16.789962,"twenty":-18.947987,"median":-11.20309,"eighty":-7.549702,"marketCap":32706846},{"date":"2025-07-18","current":-18.153613,"twenty":-18.916369,"median":-11.255905,"eighty":-7.572649,"marketCap":35363239},{"date":"2025-07-25","current":-20.113863,"twenty":-19.092292,"median":-11.268602,"eighty":-7.603246,"marketCap":39181805},{"date":"2025-07-31","current":-19.005896,"twenty":-19.142262,"median":-11.416343,"eighty":-7.649141,"marketCap":37023485}],"updateTime":1754075362955}}}